Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Emerging Research in Renal Cell Carcinoma
share announcement

Emerging Research in Renal Cell Carcinoma

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 965

Special Issue Editor

Dr. Giandomenico Roviello

E-Mail Website
Guest Editor
Department of Health Science, University of Florence, 50139 Florence, Italy
Interests: renal cell carcinoma; immunotherapy; genitourinary cancers

Special Issue Information

Dear Colleagues,

Renal cell carcinoma (RCC) is an area of active investigation, with ongoing efforts to improve the diagnosis, treatment, and management of this disease. Previous studies have focused on identifying new biomarkers for early detection, developing targeted therapies that improve outcomes and reduce side effects, and exploring the role of immune checkpoint inhibitors in RCC treatment. Recent areas of interest include the use of combination therapies, the development of predictive models to guide treatment decisions, and the use of liquid biopsies to monitor disease progression. Overall, these studies hold promise for improving outcomes for patients with RCC and advancing our understanding of this complex disease, which is the aim of this Special Issue.

Dr. Giandomenico Roviello
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • biomarkers
  • targeted therapies
  • immune checkpoint inhibitors
  • liquid biopsies

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 564 KiB  
Review
First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm
by Francesco Bloise, Fiorella Manfredi, Luca Zatteri, Giovanni Dima, Chiara Carli, Rosanna Di Vita, Maria Olivieri, Enrico Sammarco, Marco Ferrari, Alessia Salfi, Adele Bonato, Debora Serafin, Natalia Coccia, Laura Doni, Luca Galli, Michele Sisani, Giandomenico Roviello, Martina Catalano and Federico Paolieri
Cells 2024, 13(11), 961; https://doi.org/10.3390/cells13110961 - 2 Jun 2024
Viewed by 732
Abstract
The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years. The introduction of novel combination therapies involving tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors has resulted in improved oncological outcomes compared to traditional TKI monotherapy. In [...] Read more.
The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years. The introduction of novel combination therapies involving tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors has resulted in improved oncological outcomes compared to traditional TKI monotherapy. In this evolving paradigm, the pivotal role of the multidisciplinary tumor board is underscored, particularly in shaping the therapeutic trajectory for patients eligible for locoregional interventions like cytoreductive nephrectomy and metastasectomy. In cases where systemic treatment is deemed appropriate, the absence of direct comparisons among the various combination therapies complicates the selection of a first-line approach. The clinician is faced with the challenge of making decisions based on patient-specific factors such as performance status, risk classification according to the International Metastatic Renal Cell Carcinoma Database Consortium, comorbidities, and disease characteristics, including the number and location of metastases and tumor histology. Considering these concerns, we propose, as a member of a Tuscany Interdisciplinary Uro-Oncologic Group, an algorithm to streamline the decision-making process for mRCC patients, offering guidance to clinicians in their day-to-day clinical practice. Full article
(This article belongs to the Special Issue Emerging Research in Renal Cell Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop